New York State Common Retirement Fund Has $4.51 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Common Retirement Fund lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 28.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 72,315 shares of the company’s stock after selling 28,440 shares during the quarter. New York State Common Retirement Fund’s holdings in TransMedics Group were worth $4,509,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Venturi Wealth Management LLC boosted its holdings in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after purchasing an additional 219 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Quarry LP boosted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in shares of TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after purchasing an additional 322 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 5.8 %

Shares of NASDAQ:TMDX opened at $76.32 on Friday. The firm has a market cap of $2.56 billion, a P/E ratio of 81.19 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The business has a fifty day simple moving average of $67.81 and a 200 day simple moving average of $101.62.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 7.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Canaccord Genuity Group reduced their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.